Treatment of Leukemia Cutis in Chronic Lymphocytic Leukemia (CLL)

Leukemia cutis (LC) refers to the infiltration of leukemic cells into the skin. In patients with chronic lymphocytic leukemia (CLL), this cutaneous manifestation, while uncommon, represents a clinically significant finding that directs systemic management.

Clinical Scenario

This protocol addresses leukemia cutis occurring in the setting of chronic lymphocytic leukemia. Histologically confirmed LC is a rare event in CLL and most frequently occurs in patients with Richter transformation.

Treatment Approach (partial overview)

Management of leukemia cutis in CLL involves systemic therapy directed at the underlying disease. Available options include conventional immunochemotherapy as well as targeted agents — the full structured regimen specifies which agents and sequences apply to this scenario.

Complete regimen details, sequencing, and agent selection are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers15225393

However, histologically confirmed LC is a rare event in CLL and most frequently occurs in patients with Richter transformation.

Leukemia cutis of CLL can be treated with conventional immunochemotherapy and, more recently, with Bruton's tyrosine kinase inhibitors (ibrutinib, acalabrutinib, and zanubrutinib) or B cell lymphoma 2 (BCL-2) inhibitor venetoclax.

View source ↗